pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·3h ago·1 min read
save

FTC Sues Hims & Hers for Alleged Illegal Sharing of Patient Data and Deceptive Billing

Jul 30, 2026·read at BioPharma Dive ↗RegulatoryNegative

The Federal Trade Commission has filed a lawsuit against Hims & Hers, a California‑based telehealth company, accusing it of violating privacy laws.

The complaint says the firm used tracking pixels on its website that sent patients' health information to third‑party advertising platforms such as Meta and Snap without consent.

The agency also alleges Hims & Hers made it hard for users to cancel subscriptions and billed patients for prescription medications before they had a consultation with a provider.

Hims & Hers called the claims “baseless,” saying the FTC is misinterpreting the law.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices”

read at BioPharma Dive ↗
694 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoJ&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6BBioPharma Dive
  • 22h agoCapricor Duchenne cell therapy voted down by FDA panelBioPharma Dive
  • 22h agoMapLight CEO on what investors missed in the biotech’s schizophrenia dataBioPharma Dive
  • 1d agoCaldera, Vidya add to recent flurry of biotech mergersBioPharma Dive
  • 1d agoAbCellera, Vertex partner on next-gen T-cell engagersBioPharma Dive